

Francois P Duhoux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4995354/publications.pdf>

Version: 2024-02-01

57
papers

2,158
citations

471371

17
h-index

233338

45
g-index

58
all docs

58
docs citations

58
times ranked

3783
citing authors

#	ARTICLE	IF	CITATIONS
1	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	13.9	789
2	Phase I Study of ⁶⁸ Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 27-33.	2.8	317
3	A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 677.	3.4	167
4	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. <i>Annals of Oncology</i> , 2018, 29, 2334-2340.	0.6	97
5	Somatic Uniparental Isodisomy Explains Multifocality of Glomuvenous Malformations. <i>American Journal of Human Genetics</i> , 2013, 92, 188-196.	2.6	71
6	Phase I Trial of ¹³¹ I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1097-1105.	2.8	67
7	<i>PRDM16</i> (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. <i>British Journal of Haematology</i> , 2012, 156, 76-88.	1.2	48
8	KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocytopenia. <i>Leukemia</i> , 2010, 24, 1052-1055.	3.3	39
9	Window of opportunity studies: Do they fulfil our expectations?. <i>Cancer Treatment Reviews</i> , 2016, 43, 50-57.	3.4	37
10	The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy. <i>Breast</i> , 2018, 37, 114-118.	0.9	36
11	Colon Cancer: Update on Adjuvant Therapy. <i>Clinical Colorectal Cancer</i> , 2008, 7, 178-183.	1.0	35
12	Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 138-144.	2.0	26
13	Tamoxifen and Ovarian Function. <i>PLoS ONE</i> , 2013, 8, e66616.	1.1	26
14	The t(1;9)(p34;q34) fusing ABL1 with SFPO, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias. <i>Leukemia Research</i> , 2011, 35, e114-e117.	0.4	25
15	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradator, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5760-5770.	3.2	25
16	Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. <i>Medical Hypotheses</i> , 2013, 81, 707-712.	0.8	24
17	Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial. <i>PLoS ONE</i> , 2019, 14, e0225748.	1.1	20
18	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18

#	ARTICLE	IF	CITATIONS
19	The t(11;19)(q23;p13) fusing MLL with MYO1F is recurrent in infant acute myeloid leukemias. <i>Leukemia Research</i> , 2011, 35, e171-e172.	0.4	17
20	Routine use of gene panel testing in hereditary breast cancer should be performed with caution. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 33-39.	2.0	17
21	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. <i>European Journal of Human Genetics</i> , 2016, 24, 99-105.	1.4	17
22	Interobserver Variability in Ductal Carcinoma In Situ of the Breast. <i>American Journal of Clinical Pathology</i> , 2020, 154, 596-609.	0.4	17
23	Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies. <i>PLoS ONE</i> , 2011, 6, e26311.	1.1	17
24	Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer. <i>Annals of Diagnostic Pathology</i> , 2020, 49, 151634.	0.6	13
25	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	2.3	13
26	Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II. <i>Journal of Clinical Oncology</i> , 2018, 36, 1050-1050.	0.8	12
27	MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice. <i>Cancers</i> , 2022, 14, 1488.	1.7	11
28	Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. <i>European Journal of Cancer</i> , 2022, 166, 300-308.	1.3	11
29	Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases. <i>JAMA Oncology</i> , 2022, , .	3.4	11
30	Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 9922.	1.6	10
31	Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II. <i>Journal of Clinical Oncology</i> , 2017, 35, 1062-1062.	0.8	10
32	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 125.	2.3	9
33	Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application. <i>PLoS ONE</i> , 2016, 11, e0148957.	1.1	9
34	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	2.0	9
35	Comment on "Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing": <i>Journal of the American College of Radiology</i> , 2017, 14, 582.	0.9	8
36	Characterization of Preoperative, Postsurgical, Acute and Chronic Pain in High Risk Breast Cancer Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3831.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	1.3	8
38	Antivascular Therapy for Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-16.	0.6	7
39	The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. <i>Haematologica</i> , 2015, 100, e114-e115.	1.7	7
40	Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes. <i>Leukemia Research</i> , 2011, 35, e18-e20.	0.4	6
41	UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. <i>European Journal of Cancer</i> , 2018, 103, 184-194.	1.3	6
42	Impact of Perioperative Hypnosis on Postmastectomy Chronic Pain: Preliminary Results. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986949.	0.8	6
43	Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families. <i>Breast Cancer Research</i> , 2020, 22, 36.	2.2	6
44	Hypnosis Sedation Reduces the Duration of Different Side Effects of Cancer Treatments in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 4147.	1.7	6
45	Phase I results of CAM-H2: Safety profile and tumor targeting in patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13017-e13017.	0.8	6
46	Novel head-to-head gene fusion of MLL with ZC3H13 in a JAK2 V617F-positive patient with essential thrombocythemia without blast cells. <i>Leukemia Research</i> , 2012, 36, e27-e30.	0.4	3
47	Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. <i>Acta Clinica Belgica</i> , 2020, 75, 128-135.	0.5	3
48	Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study. <i>ESMO Open</i> , 2021, 6, 100207.	2.0	3
49	Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer. <i>BMC Cancer</i> , 2021, 21, 1204.	1.1	2
50	Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 33-43.	1.4	1
51	BRCA1 Mutation: An Insidious Enemy with Multiple Facets. <i>Case Reports in Oncology</i> , 2022, 15, 238-244.	0.3	1
52	Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial. <i>Annals of Oncology</i> , 2018, 29, viii57.	0.6	0
53	A critical appraisal of quality indicators of breast cancer treatment in Belgium. <i>Annals of Oncology</i> , 2019, 30, v75.	0.6	0
54	METASTATIC BREAST CANCER: OPTIMAL IMAGING TECHNIQUES FOR BONE ONLY DISEASE. <i>Breast</i> , 2019, 48, S31-S32.	0.9	0

#	ARTICLE	IF	CITATIONS
55	148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO). <i>Annals of Oncology</i> , 2020, 31, S69.	0.6	0
56	BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2066-TPS2066.	0.8	0
57	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. <i>Cancer Research</i> , 2022, 82, PD5-06-PD5-06.	0.4	0